<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302105</url>
  </required_header>
  <id_info>
    <org_study_id>POP-RT</org_study_id>
    <nct_id>NCT02302105</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer</brief_title>
  <acronym>POP-RT</acronym>
  <official_title>Prospective Phase III Randomized Trial of Prostate Only or Whole Pelvic RadioTherapy in High Risk Prostate Cancer (POP-RT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evidence to justify the use of the pelvic field is lacking for men with high risk localized&#xD;
      prostate cancer. An additional randomized study is needed in men with a potential risk of&#xD;
      nodal involvement to test the hypothesis that the use of the pelvic field contributed to the&#xD;
      benefit observed in those studies.&#xD;
&#xD;
      This trial aims to compare the outcomes with whole pelvis RT and Prostate alone RT in&#xD;
      patients with High risk, non metastatic Prostate cancer with a Lymph nodal &gt;20% with Primary&#xD;
      5 year Biochemical failure free survival and Secondary Disease free survival, overall&#xD;
      survival, Acute toxicity, Late toxicity and QOL Patients will be randomized to one of two&#xD;
      arms Arm 1 Whole pelvis radiotherapy and Arm 2 Prostate only radiotherapy. The Dose&#xD;
      prescription will be 66 Gy in 25 fractions will be prescribed for the prostate PTV in Arm 2&#xD;
      an additional 50 Gy in 25 fractions for nodal PTV in patients in Arm 1. An overlap volume at&#xD;
      rectal-prostate interface will receive 64 Gy/25#.&#xD;
&#xD;
      All patients will receive hormone therapy starting at least 8 weeks prior to the beginning of&#xD;
      radiotherapy. They will continue the hormone therapy and later for a total duration of 2-3&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2011</start_date>
  <completion_date type="Anticipated">October 23, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Disease Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Biochemical failure is defined using the standard Phoenix consensus definition i.e. PSA&gt;2ng/ml over the nadir PSA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whole Pelvis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IGRT</intervention_name>
    <description>Image Guided RT to the prostate</description>
    <arm_group_label>Prostate Only</arm_group_label>
    <arm_group_label>Whole Pelvis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          1. Any age according to the fitness estimated by the Physician&#xD;
&#xD;
          2. Physician estimated life expectancy &gt; 5 years&#xD;
&#xD;
          3. Biopsy proven Adenocarcinoma of prostate&#xD;
&#xD;
          4. High risk prostate cancer based on Staging and Risk of Pelvic Nodal Metastases ≥ 20%&#xD;
             as per the Roach formula (2/3 PSA) + [(GS - 6) x 10] If Gleason Score 8-10 - Any PSA,&#xD;
             T1- T3a N0 M0 If Gleason Score 7 - PSA &gt; 15, T1-T3a N0 M0 If Gleason Score 6 - PSA &gt;&#xD;
             30, T1-T3a N0 M0 T3b-T4a N0 M0, Any Gleason Score, Any PSA&#xD;
&#xD;
          5. Ability to receive long term hormone therapy/ Orchidectomy&#xD;
&#xD;
          6. KPS ≥ 70 (see appendix)&#xD;
&#xD;
          7. Estimated life expectancy &gt; 5 years&#xD;
&#xD;
          8. No previous history of malignancy ≤5 years&#xD;
&#xD;
          9. No prior history of therapeutic irradiation to pelvis&#xD;
&#xD;
         10. Patient willing and reliable for follow-up and QOL&#xD;
&#xD;
         11. No major co morbidities preventing radical treatment&#xD;
&#xD;
         12. Signed study specific consent form&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Any histopathology other than Adenocarcinoma&#xD;
&#xD;
          2. Contraindication to Pelvic Radiotherapy like Inflammatory Bowel Disorders&#xD;
&#xD;
          3. No prior history of pelvic surgery&#xD;
&#xD;
          4. Uncontrolled diabetes&#xD;
&#xD;
          5. Uncontrolled cardiac co morbidity&#xD;
&#xD;
          6. Presence of nodal or distant metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr Vedang Murthy</name>
      <address>
        <city>Navi-Mumbai</city>
        <state>Maharashtra</state>
        <zip>410210</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>March 27, 2021</last_update_submitted>
  <last_update_submitted_qc>March 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tata Memorial Centre</investigator_affiliation>
    <investigator_full_name>Dr Vedang Murthy</investigator_full_name>
    <investigator_title>Dr Vedang Murthy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

